Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-30, Stock:ABBV, The news for the past five days is as follows:
2019-09-23: NEWS1: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS2: AC Immune to Earn Milestone From Lilly for Alzheimer's Drug.NEWS3: AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®.
2019-09-24: NEWS1: quot;Healthyquot; Dividend Aristocrats: 6 Great Health-Care Dividends.
2019-09-25: NEWS1: VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada.
2019-09-26: NEWS1: Citi Bullish On AbbVie As Allergan Deal Provides An Earnings Floor.NEWS2: 6 Declining Stocks in Gurus' Portfolios.NEWS3: AbbVie Is Up After Another Analyst Reconsidered Its Allergan Acquisition and Upgraded the Stock.NEWS4: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J.NEWS5: [video]AbbVie Stock Gains on Citi Upgrade to Buy and Price-Target Boost.NEWS6: AbbVie Rises 3%.
2019-09-27: NEWS1: AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug.NEWS2: FTC requests AbbVie, Allergan for more information on $63 billion deal.NEWS3: FTC requests AbbVie, Allergan for more information on $63 bln deal.NEWS4: Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction.NEWS5: AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction.NEWS6: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS7: AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes.

Answer: Rise